Medullary Thyroid Cancer Clinical Trials 2022

Browse 11 Medullary Thyroid Cancer Medical Studies Across 59 Cities

3 Phase 3 Trial · 107 Medullary Thyroid Cancer Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Afor Malignant Neoplasms

Bethesda, MD
18+
All Sexes
Background: - GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments. Objectives: - To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer. Eligibility: - Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments. Design: Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine. Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year. GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly. Participants will be monitored with frequent blood and urine tests and imaging studies. Participants will have regular follow-up visits after their year of study vaccines.
Phase 2
Waitlist Available
11 Medullary Thyroid Cancer Clinical Trials Near Me
Sherbrooke, Canada
Montreal, Canada
Torrance, CA
Edmonton, Canada
More Trial Locations
An interactive map to display trial locations for Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie, McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy, The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Cross Cancer Institute; Clinical Trials, and 86 more locations.
Most Popular References for Medullary Thyroid Cancer Clinical Trials
Frequency
Citation
Top Hospitals for Medullary Thyroid Cancer Clinical Trials
Location
Active Medullary Thyroid Cancer Clinical Trials
All Time Trials for Medullary Thyroid Cancer
First Recorded Medullary Thyroid Cancer Trial
Trials
UCSF Medical Center at Mission Bay, San Francisco, California
2
2
2017
Mayo Clinic-Jacksonville, Jacksonville, Florida
2
2
2017
Washington University Medical School, Saint Louis, Missouri
2
2
2017
Mayo Clinic in Florida, Jacksonville, Florida
2
3
2008
UCLA Medical Center, Los Angeles, California
2
2
2017
Top Treatments for Medullary Thyroid Cancer Clinical Trials
Treatment Name
Active Medullary Thyroid Cancer Clinical Trials
All Time Trials for Medullary Thyroid Cancer
First Recorded Medullary Thyroid Cancer Trial
Trials
Top Cities for Medullary Thyroid Cancer Clinical Trials
City
Active Medullary Thyroid Cancer Clinical Trials
Top Active Site for Medullary Thyroid Cancer Clinical Trials
Trial List
Houston, Texas
6
University of Texas MD Anderson Cancer Center
Boston, Massachusetts
5
Massachusetts General Hospital
Philadelphia, Pennsylvania
4
University of Pennsylvania Hospital
How many medullary thyroid cancer clinical trials are open to youth and / or seniors?
Most Recent Medullary Thyroid Cancer Clinical Trials
Phase 3 Medullary Thyroid Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
Pediatric Medullary Thyroid Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
5/2/2017
Phase 1 & 2
11/1/2012
Phase 1 & 2
Senior Friendly Medullary Thyroid Cancer Clinical Trials

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 7th, 2021

Last Reviewed: August 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.